US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

10.87 +0.02 (+0.18%)
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Monte Rosa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets
The biotechnology sector, long frozen in a capital-starved "biology winter," is showing definitive signs of a seasonal shift. On January 7, 2026, the industry witnessed a significant injection of... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
Monte Rosa Therapeutics Stock Scores Biggest Gain In Nearly A Year On $5.7B Novartis Deal For Immune-Mediated Diseases ↗
Via Stocktwits
News headline image
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk. 
Via Stocktwits
Wednesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
Conference call and webcast to be held at 8 a.m. ET on January 7, 2026 
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
Conference call and webcast to be held at 8 a.m. ET on December 16, 2025 
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q3 2025 Earnings Beat Estimates, Stock Rises ↗
Monte Rosa Therapeutics (GLUE) Q3 2025 earnings crushed estimates, with revenue of $12.8M. The stock is up on strong results and a cash runway extending into 2028. 
Via Chartmill
Topics Earnings
News headline image
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dave & Buster's Entertainment Posts Downbeat Results, Joins Adtran Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Webtoon Entertainment Shares Are Trading Higher By 48%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Here are the top movers in Monday's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments ↗
Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in payments. 
Via Benzinga
News headline image
Monday's session: gap up and gap down stocks ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Monday's pre-market session: top gainers and losers ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa (GLUE) Q2 Revenue Jumps 394% ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 Next >